SCHEMBL6690711

SCHEMBL6690711

Fc1ccc2nc(-c3ccccc3)c(CBr)cc2c1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 1/20 0.43
DHODH Q02127 10/20 0.43
PDE10A Q9Y233 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
KMT2A Q03164 2/20 0.41
POLB P06746 2/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
MAP2K4 P45985 1/20 0.39
PSMB5 P28074 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
ATM Q13315 1/20 0.38
TLR9 Q9NR96 1/20 0.38
MAPT P10636 1/20 0.37
MAPK10 P53779 1/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1879174 0.82 PDE10A (0.56) ERBB2PDE10AKDM4EALDH1A1KMT2A
SCHEMBL1891795 0.82 KDM4E (0.57) ERBB2DHODHPDE10AKDM4EALDH1A1
SCHEMBL5442127 0.81 PSMB5 (0.45) DHODHPDE10AKDM4EALDH1A1KMT2A
SCHEMBL1883204 0.80 MBNL1 (0.43) ERBB2DHODHPDE10AKDM4EALDH1A1
Bromide SCHEMBL3657824 0.80 PDE10A (0.53) ERBB2PDE10AKDM4EALDH1A1KMT2A
SCHEMBL1882121 0.78 KDM4E (0.51) ERBB2KDM4EALDH1A1KMT2APOLB
SCHEMBL3657827 0.78 PDE10A (0.51) ERBB2PDE10AKDM4EALDH1A1KMT2A
SCHEMBL28536199 0.78 PDE10A (0.69) DHODHPDE10AKDM4EALDH1A1KMT2A
SCHEMBL17942629 0.76 DHODH (0.52) DHODHPDE10AKDM4EALDH1A1KMT2A
SCHEMBL5908712 0.75 ALDH1A1 (0.42) KDM4EALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040102633-A1 Novel compounds GLAXOSMITHKLINE S.P.A. (IT) 2004-05-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102633-A1 Novel compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, NR1H3 ERBB2 2243/4885DHODH 533/4885PDE10A 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.